

RECEIVED
CENTRAL FAX CENTER

DEC 20 2005



Vertex Pharmaceuticals Incorporated
130 Waverly Street • Cambridge, MA 02139-4242
Tel. 617.444.6100 • Fax 617.444.6483
<http://www.vrtx.com>

FAX TRANSMISSION

To	USPTO Commissioner for Patents
Examiner	Venkataraman Balasubramanian
Fax Number	(571) 273-8300
From	Karen E. Brown
Date	December 20, 2005
Application No.	10/632,340
Attorney Docket No.	VPI/02-119 US
	Supplemental IDS
Total Pages	24

Message or Comment

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence and any documents attached hereto, are being transmitted via facsimile to the United States Patent and Trademark Office, Facsimile Number (571) 273-8300 on December 20, 2005

A handwritten signature in black ink, appearing to read "Lisa M. Romano".
Lisa M. Romano

If any problems occur with this fax transmittal, please call (617) 444-6164 immediately.

FAX Number (617) 444-6483 Legal Department

Attorney Docket No. VPI/02-119 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/632,340

RECEIVED
CENTRAL FAX CENTER

Confirmation No.: 3588

DEC 20 2005

Filing Date: August 1, 2003

Examiner: Venkataraman Balasubramanian

Group Art Unit: 1624

Applicants: Cornelia J. Forster et al.

For: COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3

December 20, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.
- Copy(ies) of references Citation No(s). C1-C2 is/are attached.
- Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.)
- A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.
- (b) No fee is believed due because:
- The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- The Information Disclosure Statement is being concurrently filed with the above-identified application.
- The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

Applicants: **Cornelia J. Forster et al.**
Application No.: **10/632,340**

- The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Applicants: **Cornelia J. Forster et al.**
Application No.: **10/632,340**

Respectfully submitted,

Karen E. Brown

Karen E. Brown, Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

Attorney Docket No. VPI/02-119 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/632,340
Confirmation No.: 3588
Filing Date: August 1, 2003
Examiner: Venkataraman Balasubramanian
Group Art Unit: 1624
Applicants: Cornelia J. Forster et al.
For: COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3

RECEIVED
CENTRAL FAX CENTER
DEC 20 2005

December 20, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.
- Copy(ies) of references Citation No(s). C1-C2 is/are attached.
- Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.).
- A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.
- (b) No fee is believed due because:
- The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- The Information Disclosure Statement is being concurrently filed with the above-identified application.
- The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

Applicants: **Cornelia J. Forster et al.**
Application No.: **10/632,340**

- The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Applicants: **Cornelia J. Forster et al.**
Application No.: **10/632,340**

Respectfully submitted,

Karen E. Brown
Karen E. Brown, Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

BEST AVAILABLE COPY

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number 10/632,340
		Filing Date August 1, 2003
		First Named Inventor Cornelia J. Forster
		Group Art Unit 1624
		Examiner Name Venkataraman Balasubramanian
		Attorney Docket Number VPI/02-119 US

U.S. PATENT DOCUMENTS								
Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Gary W. Cline et al, "Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor on Insulin-Stimulated Glucose Metabolism in Zucker Diabetic Fatty (fa/fa) Rats", Diabetes, 51: 2903-2910 (2002)
	C2	Erik J. Henriksen et al, "Modulation of Muscle Insulin Resistance by Selective Inhibition of GSK-3 in Zucker Diabetic Fatty Rats", American Journal of Physiology Endocrinology and Metabolism, 284: E892-E900 (2003).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered
--------------------	--	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.